Learn when TIDE-based Sanger sequencing can replace NGS for measuring on-target gene editing efficiency in regulated ...

Delve into the field of B7-H3 ADCs, a new contender in SCLC cancer, as Hansoh Pharma and Medilink bring momentum with ...

Explore the preclinical research catching our eye in October 2026, from AI drug design to small molecules and gene therapy ...

Known for its freezing winters, Finland is warming up to global entrepreuners and investors to boost its life science ...

As the standards of care for prostate cancer change, new drugs, combination therapies, and trials enter the therapeutic space ...

Delve into the strategy of Viatris, a company that built its reputation around generics and is steadily moving beyond to find ...

Three big bets in metabolic disease: the race to challenge Lilly and Novo, a pill that mimics exercise, and a gene therapy ...

September is often a strong month for the biopharma sector as the industry returns from the summer lull, keen on forging biotech deals.

Look into Spain's biotech, an ecosystem that has matured and transforms promissing science into ventures but faces challenges ...

Two different antibody-drug conjugates (ADCs) targeting the same protein produced remarkably similar phase 3 results in relapsed small-cell lung cancer (SCLC) at WCLC 2026. Hansoh Pharma’s risvutatug ...

Research in the field of inflammatory diseases has become one of the hottest areas of drug development, spurred on by an interest in novel therapies that have the potential to be more precise and more ...